These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Infliximab heals intestinal inflammatory lesions and restores growth in children with Crohn's disease. Borrelli O; Bascietto C; Viola F; Bueno de Mesquita M; Barbato M; Mancini V; Bosco S; Cucchiara S Dig Liver Dis; 2004 May; 36(5):342-7. PubMed ID: 15191204 [TBL] [Abstract][Full Text] [Related]
5. Factors associated with the development of intestinal strictures or obstructions in patients with Crohn's disease. Lichtenstein GR; Olson A; Travers S; Diamond RH; Chen DM; Pritchard ML; Feagan BG; Cohen RD; Salzberg BA; Hanauer SB; Sandborn WJ Am J Gastroenterol; 2006 May; 101(5):1030-8. PubMed ID: 16606351 [TBL] [Abstract][Full Text] [Related]
6. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Vermeire S; Louis E; Carbonez A; Van Assche G; Noman M; Belaiche J; De Vos M; Van Gossum A; Pescatore P; Fiasse R; Pelckmans P; Reynaert H; D'Haens G; Rutgeerts P; Am J Gastroenterol; 2002 Sep; 97(9):2357-63. PubMed ID: 12358256 [TBL] [Abstract][Full Text] [Related]
7. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Maser EA; Villela R; Silverberg MS; Greenberg GR Clin Gastroenterol Hepatol; 2006 Oct; 4(10):1248-54. PubMed ID: 16931170 [TBL] [Abstract][Full Text] [Related]
8. Treatment of perianal fistulas in Crohn's disease by local injection of antibody to TNF-alpha accounts for a favourable clinical response in selected cases: a pilot study. Asteria CR; Ficari F; Bagnoli S; Milla M; Tonelli F Scand J Gastroenterol; 2006 Sep; 41(9):1064-72. PubMed ID: 16938720 [TBL] [Abstract][Full Text] [Related]
9. Infliximab dependency in children with Crohn's disease. Duricova D; Pedersen N; Lenicek M; Hradsky O; Bronsky J; Adamcova M; Elkjaer M; Andersen PS; Vitek L; Larsen K; Lukas M; Nevoral J; Wewer V; Munkholm P Aliment Pharmacol Ther; 2009 Apr; 29(7):792-9. PubMed ID: 19183163 [TBL] [Abstract][Full Text] [Related]
10. Clinical evolution of luminal and perianal Crohn's disease after inducing remission with infliximab: how long should patients be treated? Domènech E; Hinojosa J; Nos P; Garcia-Planella E; Cabré E; Bernal I; Gassull MA Aliment Pharmacol Ther; 2005 Dec; 22(11-12):1107-13. PubMed ID: 16305724 [TBL] [Abstract][Full Text] [Related]
11. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Hyams J; Crandall W; Kugathasan S; Griffiths A; Olson A; Johanns J; Liu G; Travers S; Heuschkel R; Markowitz J; Cohen S; Winter H; Veereman-Wauters G; Ferry G; Baldassano R; Gastroenterology; 2007 Mar; 132(3):863-73; quiz 1165-6. PubMed ID: 17324398 [TBL] [Abstract][Full Text] [Related]
12. [Treatment of Crohn's disease by infliximab. About 20 cases]. Serghini M; Karoui S; Meknini M; Matri S; Kallel L; Fekih M; Boubaker J; Filali A Tunis Med; 2009 Sep; 87(9):579-82. PubMed ID: 20180377 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of Crohn's disease with anti-TNF alpha antibodies (infliximab): results of a multicentric and retrospective study]. Doubremelle M; Bourreille A; Zerbib F; Heresbach D; Metman EH; Beau P; Gournay J; Galmiche JP Gastroenterol Clin Biol; 2002 Nov; 26(11):973-9. PubMed ID: 12483127 [TBL] [Abstract][Full Text] [Related]
14. Infliximab for Crohn's disease in clinical practice: the experience of a single center in romania. Gheorghe L; Gheorghe C; Badea M; Vădan R; Pârvulescu I; Toader C; Tugui L; Papuc O; Ionescu R; Preda C; Călin I; Diculescu M Rom J Gastroenterol; 2003 Mar; 12(1):7-13. PubMed ID: 12673373 [TBL] [Abstract][Full Text] [Related]
16. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: the first 100 patients. Ricart E; Panaccione R; Loftus EV; Tremaine WJ; Sandborn WJ Am J Gastroenterol; 2001 Mar; 96(3):722-9. PubMed ID: 11280541 [TBL] [Abstract][Full Text] [Related]
17. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Rutgeerts P; Diamond RH; Bala M; Olson A; Lichtenstein GR; Bao W; Patel K; Wolf DC; Safdi M; Colombel JF; Lashner B; Hanauer SB Gastrointest Endosc; 2006 Mar; 63(3):433-42; quiz 464. PubMed ID: 16500392 [TBL] [Abstract][Full Text] [Related]
18. Infliximab in the surgical management of complex fistulating anal Crohn's disease. Talbot C; Sagar PM; Johnston MJ; Finan PJ; Burke D Colorectal Dis; 2005 Mar; 7(2):164-8. PubMed ID: 15720356 [TBL] [Abstract][Full Text] [Related]
19. The effects of infliximab maintenance therapy on health-related quality of life. Feagan BG; Yan S; Bala M; Bao W; Lichtenstein GR Am J Gastroenterol; 2003 Oct; 98(10):2232-8. PubMed ID: 14572573 [TBL] [Abstract][Full Text] [Related]